CannaPharmaRX (OTCMKTS:CPMD) & Cytokinetics (NASDAQ:CYTK) Financial Comparison

CannaPharmaRX (OTCMKTS:CPMD) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Profitability

This table compares CannaPharmaRX and Cytokinetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CannaPharmaRX	N/A	N/A	-40.68%
Cytokinetics	-14,141.74%	N/A	-67.32%

Valuation & Earnings

This table compares CannaPharmaRX and Cytokinetics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CannaPharmaRX	N/A	N/A	$3.69 million	($0.01)	-1.10
Cytokinetics	$7.53 million	831.14	-$526.24 million	($5.40)	-11.05

CannaPharmaRX has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than CannaPharmaRX, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

CannaPharmaRX has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for CannaPharmaRX and Cytokinetics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CannaPharmaRX	0	0	0	0	N/A
Cytokinetics	0	3	15	0	2.83

Cytokinetics has a consensus price target of $77.06, indicating a potential upside of 29.10%. Given Cytokinetics’ higher probable upside, analysts clearly believe Cytokinetics is more favorable than CannaPharmaRX.

Summary

CannaPharmaRX beats Cytokinetics on 6 of the 9 factors compared between the two stocks.

About CannaPharmaRX

CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.